The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses difficult to treat indolent hematological disease patient groups at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He introduces groups in which treatment is still a challenge, including follicular lymphoma patients who progress within two years of CHOP chemotherapy, as well as the group of patients who progress soon after treatment with anti-CD20 and alkylating agent therapy. He also speaks about the GADOLIN trial (NCT01059630) in rituximab-refractory indolent non-Hodgkin lymphoma (NHL), as well as the potential of stem cell transplantation after treatment in these patient groups.
